Emerging liquid biopsy techniques for early detection of hepatocellular carcinoma, prognostication, and disease monitoring

Arvind, Ashwini; Singal, Amit G.

doi:10.1002/cld.1232

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, multiple new panels, including biomarkers such as multiprotein-based and circulating tumor-derived DNA-based (“liquid biopsy”) panels[ 88 ], as well as abbreviated magnetic resonance imaging protocols and other imaging-based protocols, are currently under investigation as potential screening tests. Studies investigating the accuracy of liquid biopsies are ongoing.…”

Section: Novel Perspectives In Surveillance For Hcc In Nafldmentioning

confidence: 99%

“…Liquid biopsy strategies for sampling tumor products in the bloodstream include substances such as circulating tumor cells (CTCs), circulating tumor DNA (ct-DNA) and extracellular vesicles (EVs)[ 88 ]. CTCs include cells released from primary or metastatic tumor sites, CT-DNA consists of DNA from cellular necrosis or apoptosis, and EVs are cell membrane-derived particles such as apoptotic bodies, micro-vesicles and exosomes, containing molecular cargoes specific to the origin cell with an essential role in cell-to-cell communication[ 88 ]. Data from a systematic review with 67 studies evaluated liquid biopsy techniques for early-stage HCC detection, including studies evaluating CTCs, ct-DNA and EVs.…”

Section: Novel Perspectives In Surveillance For Hcc In Nafldmentioning

confidence: 99%

See 1 more Smart Citation

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis

Tovo¹,

Mattos²,

Coral³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Cirrhosis is an emerging major cause of the development of hepatocellular carcinoma (HCC), but in non-alcoholic fatty liver disease (NAFLD), up to 50% of patients with HCC had no clinical or histological evidence of cirrhosis. It is currently challenging to propose general recommendations for screening patients with NAFLD without cirrhosis, and each patient should be evaluated on a case-by-case basis based on the profile of specific risk factors identified. For HCC screening in NAFLD, a valid precision-based screening is needed. Currently, when evaluating this population of patients, the use of non-invasive methods can guide the selection of those who should undergo a screening and surveillance program. Hence, the objective of the present study is to review the epidemiology, the pathophysiology, the histopathological aspects, the current recommendations, and novel perspectives in the surveillance of non-cirrhotic NAFLD-related HCC.

show abstract

Section: Novel Perspectives In Surveillance For Hcc In Nafldmentioning

confidence: 99%

Section: Novel Perspectives In Surveillance For Hcc In Nafldmentioning

confidence: 99%

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis

Tovo¹,

Mattos²,

Coral³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The development of coaxial needle techniques has resulted in negligible risks of tumor dissemination [ 12 , 13 ], leading to greater acceptance of tumor biopsies. Recently, there has been increasing interest in the molecular analysis of tumor-derived circulating tumor cells (CTCs), extracellular vesicles (EVs), and cell-free circulating nucleic acids (cfDNA or cfRNA), termed “liquid biopsy” [ 14 ]. Although these approaches might be complementary, particularly when tissue samples are insufficient or unsuitable for biomarker testing [ 15 ], tissue-based analysis remains the preferred method for molecular testing when tissue is available [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Pathogenesis to management of hepatocellular carcinoma

Shetty

et al. 2022

Genes Cancer

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer whose incidence continues to rise in many parts of the world due to a concomitant rise in many associated risk factors, such as alcohol use and obesity. Although early-stage HCC can be potentially curable through liver resection, liver-directed therapies, or transplantation, patients usually present with intermediate to advanced disease, which continues to be associated with a poor prognosis. This is because HCC is a cancer with significant complexities, including substantial clinical, histopathologic, and genomic heterogeneity. However, the scientific community has made a major effort to better characterize HCC in those aspects via utilizing tissue sampling and histological classification, whole genome sequencing, and developing viable animal models. These efforts ultimately aim to develop clinically relevant biomarkers and discover molecular targets for new therapies. For example, until recently, there was only one approved systemic therapy for advanced or metastatic HCC in the form of sorafenib. Through these efforts, several additional targeted therapies have gained approval in the United States, although much progress remains to be desired. This review will focus on the link between characterizing the pathogenesis of HCC with current and future HCC management.

show abstract

Emerging liquid biopsy techniques for early detection of hepatocellular carcinoma, prognostication, and disease monitoring

Cited by 2 publications

References 10 publications

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis

Pathogenesis to management of hepatocellular carcinoma

Contact Info

Product

Resources

About